AI Uncovers Rare Mutations with Major Impact on Heart Health

Researchers at the Icahn School of Medicine at Mount Sinai have discovered unusual coding variants in 17 genes that provide insight into the molecular causes of coronary artery disease (CAD), the world's leading cause of morbidity and mortality. They have done this by using advanced artificial intelligence technology.

The study, published in the journal Nature Genetics, identified genetic variables that influence heart disease and pave the way for more specialized and individualized approaches to cardiovascular therapy.

As previously reported by the authors in The Lancet, the researchers employed an in silico, or computer-derived, score for coronary artery disease (ISCAD) that holistically captures CAD. The ISCAD score incorporates hundreds of distinct clinical data from the electronic health record, such as vital signs, test results, prescriptions, symptoms, and diagnoses.

They conducted a thorough meta-analysis using the electronic health records of 604,914 people from the UK Biobank, All of Us Research Program, and BioMe Biobank to train machine learning models and calculate the score.

Next, the score was compared with extremely rare and rare coding variations identified in these people's exome sequences. The research team also analyzed the identified genes to examine, among other things, their participation in causative CAD risk factors, clinical symptoms of CAD, and their relationships with CAD status in conventional large-scale genome-wide association studies.

Our findings help us understand how these 17 genes are involved in coronary artery disease. Some of these genes are already known to influence heart disease development, while others have never been linked to it before. Our study shows how machine learning tools can uncover genetic insights that traditional methods might miss when comparing cases and controls. This could lead to new ways to identify biological mechanisms of heart disease or gene targets for treatment.”

Ron Do, PhD, Senior Study Author and the Charles Bronfman Professor, Personalized Medicine, Icahn School of Medicine at Mount Sinai

Rare coding variations, found in a small number of people, can significantly affect an individual's risk or susceptibility to disease when they are present. Consequently, research on these variants can help determine treatment targets and is crucial to comprehending the genetic basis of disorders.

The difficulties encountered over the past 10 years in locating uncommon coding variants linked to CAD using conventional techniques that depend on cases and controls that have been identified served as the impetus for the investigation. The inability of diagnostic codes to adequately represent the intricacy of CAD led the investigators to look into alternative lines of inquiry.

Our previous Lancet paper showed that a machine learning model trained with electronic health records can generate an in silico score for coronary artery disease, capturing disease across its spectrum, based on these findings, we hypothesized that the in-silico score for CAD could reveal novel rare coding variants related to CAD by offering a more holistic view of the disease.”

Ben Omega Petrazzini, BS, Study Lead Author and Associate Bioinformatician, Icahn School of Medicine at Mount Sinai

To further their ongoing efforts to understand disease mechanisms better, find new treatments, and enhance patient outcomes, the researchers now intend to look into the role of the identified genes in CAD biology and consider possible uses of machine learning in the genetic study of other complex diseases.

Source:
Journal reference:

Petrazzini, B. O., et al. (2024) Exome sequence analysis identifies rare coding variants associated with a machine learning-based marker for coronary artery disease. Nature Genetics. doi.org/10.1038/s41588-024-01791-x

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study Provides a New Way to Measure Healthy Microbiomes in the Gut and Soil